

- 35 -

Claims

1. A pharmaceutical composition comprising cannabidiol (CBD) and Δ^9 -tetrahydrocannabinol (THC) in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof.
2. The composition of claim 1, wherein the pharmaceutical composition comprises a *Cannabis* extract comprising the CBD and the THC.
3. The composition of claim 2, wherein the *Cannabis* extract further comprises one or more terpenes and/or terpenoids.
4. The composition of claim 2 or 3, wherein the *Cannabis* extract is macerated oil or a resin.
5. The composition of claim 2 or 3, wherein the *Cannabis* extract is formed by alcohol extraction of *Cannabis* plant material.
6. The composition of claim 5, wherein the alcohol is ethanol.
7. The composition of claim 4 or 5, wherein the *Cannabis* plant material used to form the extract is dried prior to extraction.
8. The composition of any one of claims 1-7, wherein the composition is formulated for sublingual administration.
9. The composition of any one of claims 1-8, wherein the pharmaceutical composition is in the form of a liquid.
10. The composition of any one of claims 1-9, wherein the ratio of CBD:THC is from about 4:1 to 1:4.
11. The composition of any one of claims 1-10, comprising a carrier selected from olive oil, hemp oil, sesame oil, coconut oil, vegetable oil, canola oil, grape seed oil, almond oil, medium-chain triglyceride (MCT) oil, or a combination thereof.
12. A method for treating autism, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to any one of claims 1-11.

- 36 -

13. A method for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof, the method comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to any one of claims 1-11.
14. The method of claim 12 or 13, wherein treatment is maintained for at least about 12 weeks.
15. The method of any one of claims 12-14, wherein THC is administered in an amount of less than about 10 mg/day.
16. The method of any one of claims 12-15, wherein THC is administered in an amount from about 0.1-10 mg/day.
17. The method of any one of claims 12-16, wherein CBD is administered in an amount of less than about 20 mg/day.
18. The method of any one of claims 12-17, wherein CBD is administered in an amount from about 0.1-20 mg/day.
19. The method of any one of claims 12-18, wherein the pharmaceutical composition is administered twice daily.
20. The method of any one of claims 12-19, wherein the administration is sublingual administration.
21. Use of CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 in the manufacture of a medicament for treating autism .
22. Use of CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 in the manufacture of a medicament for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

- 37 -

23. A pharmaceutical composition for treating autism comprising CBD and THC in a ratio from about 0.1:5 to about 5:0.1.
24. A pharmaceutical composition for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof, the composition comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1.
25. A kit comprising in separate parts: (a) CBD, and (b) THC, wherein the amount of CBD in part (a) and the amount of THC in part (b) are in a ratio of CBD:THC from about 0.1:5 to about 5:0.1.
26. An agent for treating autism comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1.